drugset
drugset / Trial / NCT05216341

Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

NCT05216341 ↗

Phase 2 Completed 134 enrolled OliPass Corporation Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.

Timeline

Start
2021-01-11
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject OLP-1002 Unknown 1 ug Subcutaneous
Subject OLP-1002 Unknown 2 ug Subcutaneous
Subject OLP-1002 Unknown 3 ug Subcutaneous
Subject OLP-1002 Unknown 10 ug Subcutaneous
Subject OLP-1002 Unknown 25 ug Subcutaneous
Subject OLP-1002 Unknown 50 ug Subcutaneous
Subject OLP-1002 Unknown 80 ug Subcutaneous

Indications

osteoarthritis